Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease

INTRODUCTION: We present safety results from a study of Gammagard Liquid intravenous immunoglobulin (IGIV) in patients with probable Alzheimer's disease. METHODS: This was a placebo-controlled double-blind study. Subjects were randomized to 400 mg/kg (n = 127), 200 mg/kg (n = 135) IGIV, or to 0...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Alzheimers Dement (N Y)
Auteurs principaux: Gelmont, David, Thomas, Ronald G., Britt, Jonathan, Dyck-Jones, Jacqueline A., Doralt, Jennifer, Fritsch, Sandor, Brewer, James B., Rissman, Robert A., Aisen, Paul
Format: Artigo
Langue:Inglês
Publié: Elsevier 2016
Sujets:
Featured Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5644268/
https://ncbi.nlm.nih.gov/pubmed/29067300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2016.06.003
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires